STOCK TITAN
  1. Home
  2. Sec-filings
  3. JATT
  4. [8-K] JATT II Acquisition Corp. Reports Material Event

JATT II Acquisition (NASDAQ: JATT) completes $60M SPAC IPO raise

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

JATT II Acquisition Corp completed its initial public offering of 6,000,000 ordinary shares at $10.00 per share, generating gross proceeds of $60,000,000. Underwriters have a 45-day option to buy up to 900,000 additional shares at the same price.

At the IPO closing, the sponsor bought 300,000 private placement shares at $10.00 each, adding $3,000,000. A total of $60,000,000 from the IPO and private placement was deposited into a U.S.-based trust account to fund a future business combination, subject to specified redemption and charter amendment conditions.

In connection with the IPO, the company appointed four independent directors, constituted its board committees, and adopted an amended and restated charter in the Cayman Islands. JATT II is a healthcare-focused special purpose acquisition company targeting biotechnology and life sciences businesses.

Positive

  • None.

Negative

  • None.

Insights

JATT II raises $60M in SPAC IPO and funds trust for future deal.

JATT II Acquisition Corp has completed a SPAC IPO of 6,000,000 shares at $10.00, plus 300,000 $10.00 private placement shares bought by the sponsor. Gross proceeds of $60,000,000 were generated from the IPO alone.

A total of $60,000,000 from the IPO and private placement has been placed into a trust account, to be used for an initial business combination or returned through redemptions if no deal occurs within 24 months of the IPO closing. The underwriters’ 45-day option for up to 900,000 extra shares provides additional potential capital.

The company is a healthcare-focused SPAC aiming at biotechnology and broader life sciences targets using data-driven approaches. Actual impact for shareholders will depend on whether JATT II completes a value-creating business combination within the stated 24‑month window and on subsequent shareholder redemption levels.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
IPO shares 6,000,000 shares Ordinary shares sold in initial public offering
IPO price $10.00 per share Offering price for IPO ordinary shares
IPO gross proceeds $60,000,000 Gross proceeds from the IPO before expenses
Private placement shares 300,000 shares Sponsor private placement ordinary shares at IPO closing
Private placement proceeds $3,000,000 Gross proceeds from sale of private placement shares
Trust funding $60,000,000 Total amount placed in U.S.-based trust account
Over-allotment option 900,000 shares Maximum additional shares underwriters may buy within 45 days
Business combination deadline 24 months Period from IPO closing to complete initial business combination
special purpose acquisition company financial
"a newly organized special purpose acquisition company formed as a Cayman Islands exempted company"
A special purpose acquisition company (SPAC) is a company formed with the sole purpose of raising money through a public offering to buy or merge with an existing private business. It acts like a vehicle that allows private companies to go public more quickly and with less complexity. For investors, it offers an opportunity to invest early in a potential acquisition, though it also carries risks if the intended deal doesn’t materialize.
over-allotment option financial
"a 45 day over-allotment option to purchase up to an additional 900,000 Ordinary Shares"
An over-allotment option is a special agreement that allows underwriters to sell more shares than initially planned if demand is high. Think of it like a retailer offering extra units of a popular product to meet additional customer interest. This option helps ensure the full sale is completed and can also give investors extra shares if they want more.
trust account financial
"were placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company"
A trust account is a special bank or brokerage account where assets are held and managed by a designated person or firm (the trustee) for the benefit of another person or group (the beneficiary). It matters to investors because it separates assets from personal or corporate funds, can protect assets, control how and when money is used, and may affect tax or legal rights—think of it as a locked drawer opened only under agreed rules.
amended and restated memorandum and articles of association regulatory
"the Company filed its amended and restated memorandum and articles of association"
redemption rights financial
"the Sponsor has agreed to waive its redemption rights with respect to the Private Placement Shares"
Redemption rights are contractual provisions that allow a holder of a security—such as preferred shares, bonds, or certain fund units—to require the issuer to buy back the security under specified conditions, often at a set price or by a defined formula. For investors they act like a return policy that offers a forced exit or downside protection, affecting a security’s value, liquidity and the issuer’s cash planning.
registration rights financial
"they are entitled to registration rights"
Registration rights are contractual promises that let investors require a company to file paperwork with securities regulators so those investors can sell their shares to the public. They matter because they create a path to liquidity and an exit plan—without them, investors may be stuck holding shares for a long time. Think of them like a reserved ticket that guarantees access to a public marketplace when the holder is ready to sell.
Understanding 8-K Material Events →
false --12-31 0002112446 00-0000000 0002112446 2026-04-20 2026-04-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

 

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): April 20, 2026

 

JATT II ACQUISITION CORP

(Exact name of registrant as specified in its charter)

 

Cayman Islands   001-43237   N/A
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)       Identification No.)

 

153 Central Avenue
C/O 56
Westfield, NJ 07091

(Address of principal executive offices, including zip code)

 

201-688-0364

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)  

Name of each exchange on

which registered

ordinary shares, par value $0.0001 per share   JATT   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

☒ Emerging growth company

 

☐If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

  

Item 1.01. Entry into Material Definitive Agreement.

 

On April 20, 2026, JATT II Acquisition Corp (the “Company”) consummated its initial public offering (the “IPO”) of 6,000,000 ordinary shares, par value $0.0001 per share (the “Ordinary Shares”). The Ordinary Shares were sold at a price of $10.00 per share, generating gross proceeds to the Company of $60,000,000. The underwriters for the IPO have a 45 day over-allotment option to purchase up to an additional 900,000 Ordinary Shares at a price of $10.00 per share.

 

In connection with the IPO, the Company entered into the following agreements, forms of which were previously filed as exhibits to the Company’s Registration Statement on Form S-1 (File No. 333-294294) for the IPO, originally filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 13, 2026 (as amended, the “Registration Statement”):

 

●An Underwriting Agreement, dated April 16, 2026, between the Company and Guggenheim Securities, LLC, a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.

 

  ● A Letter Agreement, dated April 16, 2026 (“Letter Agreement”), among the Company, the Company’s sponsor, JATT Ventures II L.P. (the “Sponsor”) and each of the officers and directors of the Company, a copy of which is attached as Exhibit 10.1 hereto and incorporated herein by reference.

 

  ● An Investment Management Trust Agreement, dated April 16, 2026, between the Company and Continental Stock Transfer & Trust Company, as trustee, a copy of which is attached as Exhibit 10.2 hereto and incorporated herein by reference.

 

  ● A Registration Rights Agreement, dated April 16, 2026, among the Company, the Sponsor and the Holders signatory thereto, a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.

 

  ● A Private Placement Shares Purchase Agreement, dated April 16, 2026 (the “Private Placement Shares Purchase Agreement”), between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 hereto and incorporated herein by reference.

 

  ● An Administrative Services and Indemnification Agreement, dated April 16, 2026, between the Company and the Sponsor, a copy of which is attached as Exhibit 10.5 hereto and incorporated herein by reference.
     
  ● Indemnity Agreements, each dated April 16, 2026 (each, an “Indemnity Agreement”), between the Company and each of its officers and directors, substantially in the form attached hereto as Exhibit 10.6.

 

The material terms of such agreements are fully described in the Company’s final prospectus, dated April 17, 2026, as filed with the Commission on April 17, 2026 (the “Prospectus”) and are incorporated herein by reference.

 

Item 3.02. Unregistered Sales of Equity Securities.

 

Simultaneously with the closing of the IPO, pursuant to the Private Placement Shares Purchase Agreement, the Company completed the private sale of 300,000 Ordinary Shares (the “Private Placement Shares”) at a purchase price of $10.00 per Private Placement Share, to the Sponsor, generating gross proceeds to the Company of $3,000,000. The Private Placement Shares are identical to the Ordinary Shares sold in the IPO, except that, so long as they are held by the Sponsor and its permitted transferees: (i) they may not, subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the completion of a business combination and (ii) they are entitled to registration rights.

 

1

 

 

In addition, the Sponsor has agreed to waive its redemption rights with respect to the Private Placement Shares in connection with (i) the consummation of the Company’s initial business combination, or (ii) a shareholder vote to approve an amendment to the Company’s amended and restated memorandum and articles of association to modify the substance or timing of the Company’s obligation to redeem 100% of the Ordinary Shares sold in the IPO if the Company has not consummated a business combination within 24 months of the closing of the IPO (or such other time period pursuant to an amendment to the Amended Charter (as defined below)) or with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity. 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On April 16, 2026, in connection with the IPO, Mr. Verender S. Badial, Mr. Christopher Staral, Dr. Dr. Arjun Goyal, and Dr. Jonathon Kluft (the “Directors”) were appointed to the board of directors of the Company (the “Board”). The Directors are independent directors. Effective April 16, 2026, the Directors were also appointed to the Board’s (i) Audit Committee, with Mr. Badial serving as chair of the Audit Committee, (ii) Compensation Committee, with Dr. Kluft serving as chair of the Compensation Committee and (iii) Nominating and Corporate Governance Committee, with Mr. Staral serving as chair of the Nominating and Corporate Governance Committee.

  

In connection with their appointments to the Board, each Director entered into the Letter Agreement as well as an Indemnity Agreement with the Company.

 

Other than the foregoing, none of the Directors are party to any arrangement or understanding with any person pursuant to which they were appointed as directors, nor are they party to any transactions required to be disclosed under Item 404(a) of Regulation S-K involving the Company.

 

The foregoing descriptions of the Letter Agreement and the form of indemnity agreement do not purport to be complete and are qualified in their entireties by reference to the Letter Agreement and form of indemnity agreement, copies of which are attached as Exhibits 10.1 and 10.6 hereto, respectively, and are incorporated herein by reference.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

 

On April 16, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended Charter”) with the Cayman Islands General Registry, effective the same day. The terms of the Amended Charter are set forth in the Registration Statement on pages 142 to 144 and are incorporated herein by reference. A copy of the Amended Charter is attached as Exhibit 3.1 hereto and incorporated herein by reference.

 

Item 8.01. Other Events.

 

A total of $60,000,000 comprised of the net proceeds from the IPO and the sale of the Private Placement Shares were placed in a U.S.-based trust account maintained by Continental Stock Transfer & Trust Company, acting as trustee. Except with respect to interest earned on the funds in the trust account that may be released to the Company to pay its taxes and up to $100,000 of interest to pay dissolution expenses, the funds held in the trust account will not be released from the trust account until the earliest of (i) the completion of the Company’s initial business combination, (ii) the redemption of the Ordinary Shares sold in the IPO (the “public shares”) if the Company is unable to complete its initial business combination within 24 months from the closing of the IPO, subject to applicable law or (iii) the redemption of any of the Company’s public shares properly tendered in connection with a shareholder vote to amend the Amended Charter (A) to modify the substance or timing of its obligation to allow redemption in connection with the Company’s initial business combination or to redeem 100% of the Company’s public shares if it does not complete its initial business combination within 24 months from the closing of the IPO or (B) with respect to any other provision relating to shareholders’ rights or pre-business combination activity.

  

On April 16, 2026, the Company issued a press release announcing the pricing of the IPO, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

On April 20, 2026, the Company issued a press release announcing the closing of the IPO, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K.

 

2

 

  

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

EXHIBIT INDEX

 

Exhibit No.   Description
1.1   Underwriting Agreement, dated April 16, 2026, between the Company and Guggenheim Securities, LLC.
3.1   Amended and Restated Memorandum and Articles of Association.
10.1   Letter Agreement, dated April 16, 2026, among the Company, JATT Ventures II L.P. and each of the officers and directors of the Company.
10.2   Investment Management Trust Agreement, dated April 16, 2026, between the Company and Continental Stock Transfer & Trust Company, as trustee.
10.3   Registration Rights Agreement, dated April 16, 2026, among the Company, JATT Ventures II L.P. and the Holders signatory thereto.
10.4   Private Placement Shares Purchase Agreement, dated April 16, 2026, between the Company and JATT Ventures II L.P.
10.5   Administrative Services and Indemnification Agreement, dated April 16, 2026, between the Company and JATT Ventures II L.P..
10.6   Form of Indemnity Agreement (incorporated by reference to Exhibit 10.8 to the Company’s Registration Statement on Form S-1 (File No. 333-294294), filed with the Securities and Exchange Commission on March 13, 2026).
99.1   Press Release, dated April 16, 2026.
99.2   Press Release, dated April 20, 2026.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

3

 

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  JATT II Acquisition Corp
   
Date: April 20, 2026 By: /s/ Someit Sidhu
  Name: Someit Sidhu
  Title: Chief Executive Officer

  

4

 

Exhibit 99.1

 

JATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering

 

Westfield, New Jersey, United States, April 16, 2026 (GLOBE NEWSWIRE) – JATT II Acquisition Corp (the “Company”), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share. The ordinary shares are expected to trade on the Nasdaq Global Market (“NASDAQ”) under the ticker symbol “JATT” beginning April 17, 2026. The offering is expected to close on April 20, 2026, subject to customary closing conditions.

 

Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 900,000 additional ordinary shares at the initial public offering price to cover over-allotments, if any.

 

A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 16, 2026 (the “Effective Date”). The public offering is being made only by means of a prospectus. When available, copies of the prospectus relating to the offering may be obtained from Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About JATT II Acquisition Corp

 

JATT II Acquisition Corp is a newly incorporated blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. While the Company may pursue an initial business combination in any business or industry, the Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, the Company intends to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of the management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. The Company expects to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. The Company is sponsored by JATT Ventures II L.P. and is led by Dr. Someit Sidhu, Chief Executive Officer and Chairman of the Board, and Nicholas Fernandez, Chief Financial Officer. The Company’s Board of Directors also includes Verender S. Badial, Arjun Goyal, Jonathon Kluft and Christopher Staral, bringing extensive experience across biotechnology investing, company architecture, and public and private capital markets.

 

Forward-Looking Statements

 

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering (“IPO”) including the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of JATT II Acquisition Corp, including those set forth in the Risk Factors section of JATT II Acquisition Corp’s registration statement and preliminary prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. JATT II Acquisition Corp undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

 

Contacts:

 

Nicholas Fernandez

Chief Financial Officer

153 Central Avenue
C/O 56
Westfield, NJ 07091
201-688-0364

 

Exhibit 99.2

 

JATT II Acquisition Corp Announces Closing of

$60,000,000 Initial Public Offering

 

Westfield, New Jersey, United States, April 20, 2026 (GLOBE NEWSWIRE) — JATT II Acquisition Corp (the “Company”) announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share on April 20, 2026. Total gross proceeds from the offering were $60,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

 

The ordinary shares began trading on the Nasdaq Global Market (“NASDAQ”) under the ticker symbol “JATT” on April 17, 2026.

 

Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 900,000 additional ordinary shares at the initial public offering price to cover over-allotments, if any.

 

A registration statement relating to the securities sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on April 16, 2026. The public offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained from Guggenheim Securities, LLC, Attn: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

 

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About JATT II Acquisition Corp

 

JATT II Acquisition Corp is a newly incorporated blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The Company has not selected any specific business combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with the Company. While the Company may pursue an initial business combination in any business or industry, the Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. In particular, the Company intends to seek businesses that can benefit from the clinical, scientific, operational, strategic and capital markets experience of the management team and board of directors and, in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing visibility with investors and potential partners. The Company expects to focus particularly, though not exclusively, on businesses applying data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve the therapeutic discovery and development process. The Company is sponsored by JATT Ventures II L.P. and is led by Dr. Someit Sidhu, Chief Executive Officer and Chairman of the Board, and Nicholas Fernandez, Chief Financial Officer. The Company’s Board of Directors also includes Verender S. Badial, Arjun Goyal, Jonathon Kluft and Christopher Staral, bringing extensive experience across biotechnology investing, company architecture, and public and private capital markets. Learn more at www.jattacquisition.com.

 

Forward-Looking Statements

 

This press release contains statements that constitute “forward-looking statements,” including with respect to the Company’s initial public offering (“IPO”) including the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination. No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of JATT II Acquisition Corp, including those set forth in the Risk Factors section of JATT II Acquisition Corp’s registration statement and prospectus for the IPO filed with the SEC. Copies are available on the SEC’s website, www.sec.gov. JATT II Acquisition Corp undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

 

Contacts:

 

Nicholas Fernandez

Chief Financial Officer

153 Central Avenue
C/O 56
Westfield, NJ 07091
201-688-0364

 

Source: View Original Filing on SEC EDGAR

FAQ

What did JATT (JATT II Acquisition Corp) announce in this 8-K filing?

JATT II Acquisition Corp reported completion of its initial public offering of 6,000,000 ordinary shares at $10.00 per share, raising gross proceeds of $60,000,000, alongside a sponsor private placement and related governance and charter actions tied to its SPAC structure.

How much capital did JATT II Acquisition Corp (JATT) raise in its SPAC IPO?

JATT II Acquisition Corp raised gross proceeds of $60,000,000 from selling 6,000,000 ordinary shares at $10.00 per share. In addition, its sponsor purchased 300,000 private placement shares at $10.00 each, contributing a further $3,000,000 of capital to support the SPAC’s operations.

What is the purpose of the $60,000,000 trust account for JATT (JATT II Acquisition Corp)?

JATT II Acquisition Corp placed $60,000,000 into a U.S.-based trust account to fund an initial business combination or future shareholder redemptions. Funds can be released upon a completed transaction, required redemptions, or dissolution events, with limited interest permitted for taxes and dissolution expenses.

What over-allotment option did JATT II Acquisition Corp (JATT) grant its underwriters?

JATT II Acquisition Corp granted underwriters a 45-day option to purchase up to 900,000 additional ordinary shares at the initial public offering price of $10.00 per share. This option allows potential expansion of the IPO’s size if investor demand warrants additional allocations.

What private placement did the sponsor of JATT II Acquisition Corp (JATT) complete?

At IPO closing, the sponsor bought 300,000 private placement ordinary shares at $10.00 per share, generating $3,000,000 in gross proceeds. These shares carry transfer restrictions, registration rights, and waived redemption rights in specified business combination and charter amendment scenarios.

What type of companies does JATT II Acquisition Corp (JATT) plan to target?

JATT II Acquisition Corp is a blank check company focused on healthcare and healthcare-related businesses, emphasizing biotechnology and broader life sciences. It intends to prioritize data-driven firms using tools like machine learning, computational biology and structure-based drug design in therapeutic discovery.

What governance and charter steps did JATT II Acquisition Corp (JATT) take with its IPO?

In connection with the IPO, JATT II Acquisition Corp appointed four independent directors, formed its audit, compensation, and nominating and corporate governance committees, and filed an amended and restated memorandum and articles of association in the Cayman Islands to govern its SPAC structure.

Filing Exhibits & Attachments

12 documents

Press Releases

Agreements & Contracts

Other Documents